Alzheimer's prevention seen promising as drug cures fail



Three studies set to explore the use of experimental drugs that may become the first to change the course of Alzheimer's disease aren't looking to cure the illness. Their goal is to prevent it altogether.

The independent trials will begin in 2013 and run for three to five years, testing as many as five drugs in almost 1,500 volunteers who haven't shown any of Alzheimer's mind-altering symptoms, yet carry a strong genetic risk for the disease or display early physical evidence in the brain. A decision on the final study drug is expected in December.

The newest strategy abandons a drive that failed to stop Alzheimer's once memories recede. Instead, as with heart disease, scientists are exploring if the mind-robbing ailment can be prevented or at least delayed using drugs that act roughly like Pfizer's Lipitor and other statins. The idea, driven by new information that tracks the disease's progression back through time, is to act years before symptoms occur to rid the brain of proteins that can later destroy nerve cells.

"We now can see changes 10 to 15 years before symptoms develop," said Neil Buckholtz, director of the division of neuroscience at the National Institute on Aging in Bethesda, Maryland. "If you can stop them, you have a chance of slowing down or possibly even stopping progression."

A breakthrough can't come soon enough. The number of Alzheimer's cases globally is expected to double within 20 years as the world's population ages, to as many as 65.7 million people in 2030 and 115 million by 2050, the Geneva- based World Health Organization said in April.

At the same time, studies completed as recently as the last three months involving drugs made by Pfizer and Johnson & Johnson, the world's two biggest makers of health products, and Eli Lilly & Co. showed virtually no progress in slowing or stopping the disease in patients in the later stages of the disease.

Lilly said on Oct. 8 that its drug, solanezumab, provided no benefit to advanced victims in a trial. The research did suggest the medicine may help in a small way in those with early symptoms. J&J and Pfizer reported on Sept. 11 that while their drug, bapineuzumab, showed signs of reducing physical damage, it didn't affect symptoms.

The next step, Buckholtz said, is to determine if pushing the use of drugs like these back in time, when the disease is just beginning to form, will make a difference.

"Really what's happened is over the past 10 years, investigators have tried to go earlier and earlier in the disease process," Buckholtz said.

Enabling researchers to get an ever earlier look at the progression of Alzheimer's has been the development of new imaging agents, such as Pittsburgh Compound B or PiB, that highlights the activity of beta amyloid, the hallmark protein that makes up the brain's tell-tale tangles.

Researchers studying those with a genetic propensity for early Alzheimer's, which can take hold by age 40, have also tracked changes in brain size and cerebrospinal fluid that can occur as early as 25 years before symptoms develop.

That work has allowed scientists to think of Alzheimer's as a kind of chain reaction, much like that leading up to heart disease, said Randall Bateman, a neurologist at the Washington University in St. Louis who is leading one of the three studies.

"The questions are how long do you treat, when do you start, and how do you measure effectiveness," Bateman said in a telephone interview. "It took thousands of patients over many years to show statins have a benefit in heart disease. We're going as early in Alzheimer's as we practically can."

While the three studies won't help those with the disease now, they may be able affect the lives of generations to come, the researchers said.

Researchers in two of the trials have already determined they'll use Lilly's solanezumab and two products made by Roche Holding that are in earlier stages of testing.

One of these trials is led by Bateman and the other by Eric Reiman of the Banner Alzheimer's Institute in Phoenix. These studies will test about 460 people, all of whom have rare genetic mutations that almost certainly will trigger the disease early in their lives.

Bateman's team will, over at least three years, test as many as three drugs in 160 people with parents who fell victim to the disease early.

Reiman's group will study a group of families in Colombia who often suffer severe memory loss by their early 40s. The five-year $100 million study has interim tests that may indicate whether the drug is having an effect within two years.

The third trial, dubbed A4, will be conducted by a team led by Reisa Sperling at Harvard Medical School in Boston. It will test a drug on about 1,000 older people over three years whose brains show the beginning of physical signs of Alzheimer's characteristic beta amyloid protein deposits, and who haven't yet displayed the disease's symptoms.

A4 is the most representative of the general population, and researchers plan to decide in December which drug they will test, Sperling, a neurologist, said in a telephone interview. She declined to say which medicines are being considered.

"It's challenging to make a decision," she said. "We're looking for a combination of evidence of biologic activity and a hint of clinical efficacy. That's much more difficult because the drugs right now are all being tested in dementia, so it's hard to know how to extrapolate the findings back 10 years."

The researchers also want to make sure the drugs are safe, because the study group is composed of clinically normal older adults, Sperling said.

The trials are exploratory, said Maria Carrillo, the vice president of medical and scientific relations at the Alzheimer's Association, a Chicago-based advocacy organization. Any drug that's at least being studied in a Phase 2 trial targeting amyloid is fair game, she said.

"The question is, if we can really effect and impact that in a significant way," Washington University's Bateman said. "It would be a fantastic breakthrough for these family members, and having that demonstration we can treat and prevent the disease will embolden the field."

Start your day with The Independent, sign up for daily news emails
Have you tried new the Independent Digital Edition apps?
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Recruitment Genius: Bookkeeper / Office Co-ordinator

£9 per hour: Recruitment Genius: This role is based within a small family run ...

Recruitment Genius: Designer - Print & Digital

£28000 - £32000 per annum: Recruitment Genius: This Design and marketing agenc...

Recruitment Genius: Quantity Surveyor

£46000 per annum: Recruitment Genius: This property investment firm are lookin...

Recruitment Genius: Telesales / Telemarketing Executive - OTE £30k / £35k plus

£18000 - £35000 per annum: Recruitment Genius: This company specialises provid...

Day In a Page

War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

The battle for Mosul will unleash 'a million refugees'

Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn
Yvette Cooper: We can't lose the election. There's too much on the line

Yvette Cooper: We can't lose the election. There's too much on the line

The shadow Home Secretary on fighting radical Islam, protecting children, and why anyone in Labour who's thinking beyond May must 'sort themselves out'
A bad week for the Greens: Leader Natalie Bennett's 'car crash' radio interview is followed by Brighton council's failure to set a budget due to infighting

It's not easy being Green

After a bad week in which its leader had a public meltdown and its only city council couldn't agree on a budget vote, what next for the alternative party? It's over to Caroline Lucas to find out
Gorillas nearly missed: BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter

Gorillas nearly missed

BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
Downton Abbey effect sees impoverished Italian nobles inspired to open their doors to paying guests for up to €650 a night

The Downton Abbey effect

Impoverished Italian nobles are opening their doors to paying guests, inspired by the TV drama
China's wild panda numbers have increased by 17% since 2003, new census reveals

China's wild panda numbers on the up

New census reveals 17% since 2003
Barbara Woodward: Britain's first female ambassador to China intends to forge strong links with the growing economic superpower

Our woman in Beijing builds a new relationship

Britain's first female ambassador to China intends to forge strong links with growing economic power
Courage is rare. True humility is even rarer. But the only British soldier to be awarded the Victoria Cross in Afghanistan has both

Courage is rare. True humility is even rarer

Beware of imitations, but the words of the soldier awarded the Victoria Cross were the real thing, says DJ Taylor
Alexander McQueen: The catwalk was a stage for the designer's astonishing and troubling vision

Alexander McQueen's astonishing vision

Ahead of a major retrospective, Alexander Fury talks to the collaborators who helped create the late designer's notorious spectacle
New BBC series savours half a century of food in Britain, from Vesta curries to nouvelle cuisine

Dinner through the decades

A new BBC series challenged Brandon Robshaw and his family to eat their way from the 1950s to the 1990s
Philippa Perry interview: The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course

Philippa Perry interview

The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course
Bill Granger recipes: Our chef recreates the exoticism of the Indonesian stir-fry

Bill Granger's Indonesian stir-fry recipes

Our chef was inspired by the south-east Asian cuisine he encountered as a teenager
Chelsea vs Tottenham: Harry Kane was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope

Harry Kane interview

The striker was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope
The Last Word: For the good of the game: why on earth don’t we leave Fifa?

Michael Calvin's Last Word

For the good of the game: why on earth don’t we leave Fifa?
HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

Scientists hail daily pill that protects against HIV infection

Breakthrough in battle against global scourge – but will the NHS pay for it?